Home › Trials › NCT02006134

Initiative to understand childhood vasculitis

Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes

Observational University of British Columbia · NCT02006134

This study is trying to gather information and samples from up to 600 children with different types of vasculitis to better understand how the disease affects them and how well treatments are working.

Quick facts

Study typeObservational
Enrollment1600 (estimated)
AgesN/A to 20 Years
SexAll
SponsorUniversity of British Columbia Academic / other
Locations32 sites (San Francisco, California and 31 other locations)
Trial IDNCT02006134 on ClinicalTrials.gov

What this trial studies

This initiative aims to collect clinical data and biological samples from up to 600 children diagnosed with various forms of childhood vasculitis, including conditions like Granulomatosis with Polyangiitis and Takayasu Arteritis. The study will gather comprehensive information from medical charts at multiple time points, including diagnosis and follow-up visits, to assess disease activity and treatment outcomes. Additionally, biological samples such as blood, urine, and saliva will be collected to better understand the disease's impact and response to treatment. The initiative is linked to an adult vasculitis study to enhance knowledge across age groups.

Who should consider this trial

Good fit: Ideal candidates include children diagnosed with ANCA-associated vasculitis or other specified forms of vasculitis before the age of 18.

Not a fit: Patients diagnosed with other vasculitis subtypes not included in the study or those over 20 years of age may not benefit from this initiative.

Why it matters

Potential benefit: If successful, this initiative could lead to improved treatment strategies and outcomes for children suffering from vasculitis.

How similar studies have performed: While this initiative builds on existing adult vasculitis studies, it focuses specifically on children, making it a novel approach in this demographic.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion criteria for vasculitis subjects:

* Diagnosed with ANCA-associated vasculitis (AAV: such as Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Microscopic Polyangiitis (MPA)), Primary Angiitis of the Central Nervous System (PACNS), Unclassified vasculitis, Takayasu's Arteritis (TA) or Polyarteritis Nodosa (PAN) before age 18

Inclusion criteria for healthy controls:

* Healthy adult or child

Exclusion Criteria for vasculitis subjects:

* Diagnosed with other vasculitis subtypes not listed above
* More than 20 years of age

Exclusion criteria for healthy controls:

* Donated greater than 20 ml of blood in the previous three weeks
* Has an immune disorder or blood borne infectious diseases (such as HIV or Hepatitis)
* Has vasculitis, multiple sclerosis, diabetes, an autoimmune disease, a thyroid condition, or other chronic conditions involving the heart, lungs, gut or kidney
* Has a previous history of anaemia or abnormal blood clotting
* Has a current or previous drug abuse problem

Where this trial is running

San Francisco, California and 31 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Wegeners GranulomatosisMicroscopic PolyangiitisEosinophilic Granulomatosis With PolyangiitisPolyarteritis NodosaTakayasu ArteritisPrimary CNS VasculitisUnclassified VasculitisVasculitis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.